Growing Biopharmaceutical Industry Is Supporting Development Across The Oral Proteins And Peptides Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Oral Proteins And Peptides Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The size of the oral proteins and peptides market has experienced substantial expansion in recent years. This market is projected to expand from $1.56 billion in 2025 to $1.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.5%. Historically, this growth has been driven by factors such as the limited oral bioavailability of proteins and peptides, a reliance on injectable formulations, the rising occurrence of diabetes and gastrointestinal disorders, increasing research efforts in peptide therapeutics, and the regulatory approvals for early oral peptide drugs.

The oral proteins and peptides market is anticipated to experience substantial growth in the coming years. It is projected to achieve a market size of $4.26 billion in 2030, expanding at a compound annual growth rate (CAGR) of 22.2%. This expected growth during the forecast period can be attributed to the development of new delivery technologies for oral proteins, the expansion of programs for managing chronic diseases, the increasing acceptance of personalized and combination therapies, a rise in healthcare spending on metabolic and hormonal disorders, and the integration of digital tools for adherence and monitoring. Significant trends for this period include the growing adoption of oral insulin and other therapeutic peptides, the advancement of personalized medicine and targeted oral protein therapies, a heightened focus on treatments for gastrointestinal disorders, the broadening of oral protein formulations for diabetes and metabolic disorders, and progress in long-acting and combination oral protein products.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

Which Major Factors Are Contributing To The Development Of The Oral Proteins And Peptides Market?

The expansion of the biopharmaceutical industry is anticipated to boost the development of the oral proteins and peptides market moving ahead. This sector, part of the wider pharmaceutical industry, concentrates on the creation, manufacturing, and marketing of medications originating from biological sources. Its expansion can be attributed to progress in biotechnology, an increasing need for personalized medicine, a higher incidence of chronic illnesses, and greater funding for research and development efforts. Within biopharmaceuticals, oral proteins and peptides present opportunities for drug delivery without invasive procedures, improving patient adherence and decreasing the reliance on injections. These substances are capable of targeting particular diseases, demonstrating enhanced stability and absorption within the digestive system. As an illustration, in October 2025, data from the Bioscience and Health Technology Sector, a source of UK government statistics, indicated that during 2023/2024, the UK life sciences industry contained 6,170 businesses operating within 7,320 companies. These entities provided employment for 359,600 individuals and achieved a turnover of £146.9 ($169.69) billion. Consequently, the expanding biopharmaceutical industry is a significant impetus behind the growth of the oral proteins and peptides market.

What Are The Core Segment Classifications In The Oral Proteins And Peptides Market?

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

Which Trends Are Guiding The Development Of The Oral Proteins And Peptides Market?

Leading firms within the oral proteins and peptides market are dedicating efforts to devising novel formulation technologies designed to improve the stability, permeability, and bioavailability of peptides when administered orally. Such innovations seek to address long-standing hurdles, including enzymatic breakdown and insufficient absorption within the gastrointestinal system. A notable example occurred in August 2025, when BioMed X, a biomedical research institute based in Germany, initiated a fresh collaborative effort with Novo Nordisk, a pharmaceutical company located in Denmark. This partnership aims to expedite the creation of advanced oral peptide delivery technologies. This collaboration intends to investigate innovative molecular approaches and administration methods to facilitate the production of oral peptide therapeutics that are safe, efficacious, and convenient for patients. Through combining BioMed X’s competencies in early-stage research with Novo Nordisk’s profound knowledge in peptide-derived medicines, the joint venture seeks to propel cutting-edge oral drug delivery solutions forward and broaden the therapeutic scope of peptide medicines across various metabolic and chronic conditions.

Who Are The Major Companies Operating In The Oral Proteins And Peptides Market?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Access The Complete Oral Proteins And Peptides Market Report:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Region Leads The Oral Proteins And Peptides Market By Size?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Oral Proteins And Peptides Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

Browse Through More Reports Similar to the Global Oral Proteins And Peptides Market 2026, By The Business Research Company

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Oral Contraceptive Pills Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report

Oral Thin Films Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-thin-films-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795